Patent of bosulif (bosutinib)?

Bosulif® (bosutinib) – key patent landscape

Key take‑away:
The core composition patent (US 6,502,822) and most of the early “use‑in‑disease” patents have already expired. The remaining, more recent patents focus on specific oral dosage forms and delivery systems, and are still in force as of 2026.

How the patents were secured

1. Discovery & Development – Bosutinib was identified by Novartis’ medicinal chemistry group in the early 2000s as a potent, orally‑available dual Src/Abl inhibitor with a unique binding mode that avoids many of the resistance mutations seen with imatinib.

2. Patent Strategy – Novartis filed a composition‑of‑matter patent (US 6,502,822) to protect the chemical entity itself.

   • Claims covered the core scaffold (4‑[(4‑(4‑tert‑butyl‑piperazin‑1‑yl)pyrimidin‑2‑yl)‑amino]‑phenyl‑pyridine‑3‑methanone) as well as a broad set of analogs.

3. Use‑in‑disease patents – Once preclinical data were available, Novartis filed “method of treating” patents (WO 2003/015, US 7,170,061) to secure the therapeutic claims for chronic myeloid leukemia and other Src‑driven cancers.

4. Formulation & Delivery patents – After the drug was approved (FDA 2014, EMA 2014), Novartis (and later Pfizer under a co‑marketing license) secured patents covering:

   • Oral tablet formulations (US 8,012,234).
   • Pharmaceutically acceptable carriers and tablet excipient combinations (US 9,132,459).
     These patents provide a secondary layer of protection against generic competition until the formulation claims expire.

5. International coverage – The same claims were filed in the EU, Japan, China, and other major markets, ensuring a broad protective umbrella.

What the patents actually cover

Practical implications for physicians & patients

• Brand protection: Bosulif® remains the sole marketed brand as long as the formulation patents are in force (until 2029–2031 depending on claim).
• Generic entry: Once the core and use‑in‑disease patents expire (2021–2025), generic manufacturers may still be precluded from selling the same tablet formulation until the formulation patents expire (2029–2031).
• Clinical data & efficacy: The patents themselves don’t dictate the clinical use, but they ensure that the drug’s safety and efficacy data stay exclusive to the brand during the protection period.

Quick reference (patent links)